Reviva Pharmaceuticals

President & CEO Laxminarayan Bhat, Ph.D. will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase on Wednesday, May 20, 2026 at 2:40 PM ET View press release for details: revivapharma.com/reviva-to-part… $RVPH

Today we reported financial results for the first quarter ended March 31, 2026 and summarized recent business highlights including. Read our full press release here: revivapharma.com/reviva-reports… $RVPH

We speak with @RevivaPharma's CEO Dr. Laxminarayan Bhat about recent M&A in the CNS space. $RVPH #schizophrenia #biopharma #biotech youtube.com/shorts/L_3faJi…

@RevivaPharma CEO Dr Laxminarayan Bhat talks with us about brilaroxazine's #ADHD indication & how it relates to other behavioral disorders. $RVPH #schizophrenia #biopharma #biotech youtube.com/shorts/0JkwB-Y…

@RevivaPharma CEO Dr Laxminarayan Bhat discusses the vocal biomarker that was developed in the RECOVER trial. $RVPH #schizophrenia #biopharma #biotech youtu.be/vngRvpKDGZ8

AGP’s James Molloy joins Reviva CEO Laxminarayan Bhat, Ph.D. to discuss the Phase 3 RECOVER-2 trial in schizophrenia and what it means for brilaroxazine across multiple neuropsychiatric indications. Watch here: vimeo.com/1188097611/1b9… $RVPH

@RevivaPharma CEO Dr Laxminarayan Bhat describes the trial design for RECOVER 2 which will evaluate schizophrenia patients with a four week regimen of brilaroxazine at 30 and 50 mg. $RVPH #schizophrenia #biopharma #biotech youtube.com/shorts/8SoS4jY…

@RevivaPharma CEO Dr Laxminarayan Bhat looks ahead to other indications for brilaroxazine and what their market potential may be. $RVPH #schizophrenia #biopharma #biotech youtube.com/shorts/IE5ZxiL…

@RevivaPharma CEO Dr Laxminarayan Bhat explains why most trials evaluating new atypical antipsychotics begin with schizophrenia and then pursue other indications in major depressive disorder and bipolar disorder later. #schizophrenia #biopharma #biotech youtube.com/shorts/-ugVYnR…

@RevivaPharma expects to use a reformulation of brilaroxazine in its RECOVER 2 trial. CEO Dr Laxminarayan Bhat identifies the three changes that will be made to extend and strengthen the patent. #schizophrenia #biopharma #biotech youtube.com/shorts/-m8rPNm…

Reviva Pharmaceuticals CEO Dr Laxminarayan Bhat outlines the brief bioequivalence studies that are underway and required to be complete before $RVPH can begin RECOVER 2. youtu.be/6RPy2_POp4o #schizophrenia #biopharma #biotech

CEO Laxminarayan Bhat, PhD, will join A.G.P. analyst James Molloy for a fireside chat on April 27 at 11 AM ET, to discuss the recent progress of brilaroxazine and upcoming clinical, regulatory, and IP milestones. Learn more: revivapharma.com/reviva-to-part… $RVPH

$RVPH @RevivaPharma Shareholder Letter Introduces New IP buff.ly/RYI1Dge by @vanjohn10

Today we reported financial results for the full year ended December 31, 2025 and summarized recent business highlights. Read our full press release here: revivapharma.com/reviva-reports… $RVPH

We speak with Dr Bhat who helps us walk through a multiple of peak anticipated revenues valuation for @RevivaPharma. youtu.be/Dpv8UQRvxuc The valuation discussed in this interview is not Zacks' official valuation which can be found in our initiation.

Reviva’s Founder, President & CEO, Laxminarayan Bhat, PhD, and CFO, Narayan Prabhu, are in San Francisco during #JPM2026, connecting with leaders across the biopharma and biotech community for a week of dynamic discussions and meaningful meetings. jpmorgan.com/about-us/event… $RVPH

Today we announced the publication of an article in Biological Psychiatry that highlights clinical vocal biomarker data from our RECOVER Phase 3 trial and the therapeutic potential of brilaroxazine for the treatment of schizophrenia. revivapharma.com/reviva-announc… $RVPH

President and CEO Laxminarayan Bhat, Ph.D. will present at the Sachs 9th Annual Neuroscience Innovation Forum, taking place January 11, 2026, in San Francisco, CA. revivapharma.com/reviva-to-pres… $RVPH

Today we announced a regulatory update following a pre-NDA meeting with the FDA regarding brilaroxazine, a novel serotonin-dopamine and neuroinflammatory signaling modulator, in late-stage development for the treatment of schizophrenia. revivapharma.com/reviva-announc… $RVPH

This recent @Benzinga Money article discusses Reviva’s progress with brilaroxazine, showcasing promising Phase 2/3 results in schizophrenia and a targeted FDA submission in 2026. Read the full article here: benzinga.com/money/reviva $RVPH